Short-chain fatty acids (SCFAs — acetate C2, propionate C3, butyrate C4) are the dominant end-products of gut bacterial fermentation of dietary fiber + resistant starch + some peptides. Concentrations in colonic lumen reach 50–150 mM total; ratio ~60:20:20 (acetate:propionate:butyrate). Functions: (1) Colonocyte fuel — butyrate is the preferred energy substrate for colonocytes (β-oxidation in mitochondria → 70% of colonocyte ATP); deficiency contributes to "starved-colonocyte" hypothesis of UC. (2) Histone deacetylase inhibition — butyrate (and propionate, weaker) inhibit class I HDACs (HDAC1/2/3/8) → hyperacetylation → tumor-suppressor gene re-expression + Treg differentiation (FoxP3 induction via HDAC inhibition + GPR43) + BDNF (cross-link bdnf trkb neurotrophic). (3) GPCR signaling — GPR43 (FFAR2) responds to acetate + propionate > butyrate → L-cell GLP-1 + PYY secretion (cross-link fxr tgr5 bile acid receptor + insulin glucose homeostasis); GPR41 (FFAR3) similar; GPR109A responds to butyrate > niacin → anti-inflammatory in macrophages. (4) Mucin synthesis + barrier function — butyrate ↑MUC2, ↑tight junctions (claudins) → gut-barrier integrity. (5) Immune regulation — local IL-10/Treg induction (mucosal immunity); systemic via SCFA spillover to portal then peripheral circulation. Clinical relevance: Clostridium difficile risk after broad-spectrum antibiotics (loss of butyrate-producing Faecalibacterium, Roseburia, Eubacterium); IBD (↓butyrate-producers); colon cancer (chemoprevention via HDAC inhibition); metabolic syndrome (↑acetate → adipogenesis + lipogenesis). Therapeutics: dietary fiber (psyllium, inulin, oat β-glucan, resistant starch) → fermentable substrate; FMT for rCDI; rifaximin (non-absorbed antibiotic) for IBS-D + HE; metformin partly works via microbiome (↑Akkermansia + butyrate-producers). Cross-links: bdnf trkb neurotrophic, fxr tgr5 bile acid receptor, insulin glucose homeostasis, ampk signaling.
Organ Systems
digestive
immune-hematologic
endocrine
Pathway Steps
dietary fiber + resistant starch (escape SI absorption) → colonic delivery (cecum + proximal colon) — via host enzymes cannot hydrolyze; reach colon intact as substrate. Dietary fiber and resistant starch escape digestion in the small intestine and reach the colon intact, delivering fermentable substrate to the dense microbial community of the cecum and proximal colon. This delivery of otherwise-indigestible carbohydrate to gut bacteria is what feeds SCFA production — the basis of fiber’s benefits.
fiber + resistant starch (colon) → SCFAs (acetate, propionate, butyrate) — via Bacteroidetes + Firmicutes fermentation; cross-feeding network (Faecalibacterium, Roseburia, Eubacterium for butyrate). Colonic bacteria ferment these carbohydrates to short-chain fatty acids — chiefly acetate, propionate, and butyrate (roughly 60:20:20). SCFAs are the major end-products of fiber fermentation and the principal currency through which the microbiome communicates with host metabolism and immunity.
butyrate (colonocyte) → mitochondrial β-oxidation → acetyl-CoA → ATP — via preferred colonocyte fuel; 70% of energy needs; deficient in UC ("starved colonocyte"). Butyrate is the preferred fuel of colonocytes: they take it up and run it through mitochondrial β-oxidation to acetyl-CoA and ATP. This local fuel use keeps the colonic epithelium in a low-oxygen state that favors beneficial anaerobes — and butyrate deficiency impairs epithelial barrier integrity.
butyrate / propionate → HDAC inhibition → histone hyperacetylation — via → Treg FoxP3 induction + tumor suppressor reactivation + BDNF promoter acetylation. At signaling concentrations, butyrate and propionate inhibit histone deacetylases (HDACs), increasing histone acetylation and reprogramming gene expression. This epigenetic action drives anti-inflammatory effects (notably promoting colonic regulatory T cells) — a major mechanism of SCFAs’ immunomodulation.
acetate / propionate → GPR43 / GPR41 (FFAR2/3) on L-cells — via → GLP-1 + PYY secretion → glucose homeostasis + satiety. Acetate and propionate are ligands at the GPCRs GPR43 (FFAR2) and GPR41 (FFAR3) on enteroendocrine L-cells and other tissues. Activating them stimulates gut-hormone secretion (GLP-1, PYY), linking fiber intake to appetite regulation, insulin secretion, and energy balance.
butyrate → GPR109A (HCA2) on macrophages + colonocytes — via → anti-inflammatory (also responds to niacin pharmacologically). Butyrate is the main ligand for GPR109A (HCA2) on colonocytes and macrophages — the same receptor niacin activates. Signaling here drives anti-inflammatory and anti-carcinogenic programs in the colon, one reason butyrate is protective against colitis and colorectal cancer.
SCFAs (luminal) → portal venous spillover → systemic — via ~95% colonic uptake; rest reaches periphery via portal; propionate is hepatic gluconeogenic substrate. SCFAs not used locally enter the portal vein and reach the liver and systemic circulation, where propionate is gluconeogenic and SCFAs influence hepatic lipid metabolism, appetite centers, and immune cells far from the gut. This is how a colonic fermentation product exerts whole-body effects.
Known Modulators
rifaximin (inhibitor) — gut bacteria broadly — alters SCFA producer composition. paradoxically often increases beneficial SCFA-producers; used in IBS-D + HE